Reckitt Benckiser Share Price (RB.)

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Reckitt Benckiser	LSE:RB.	London	Ordinary Share	GB00B24CGK77	ORD 10P

	Price Change	% Change	Share Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Shares Traded	Last Trade
	-76.00p	-0.95%	7,884.00p	7,884.00p	7,887.00p	7,966.00p	7,879.00p	7,950.00p	940,652	16:35:23

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Household Goods & Home Construction	9,891.0	2,394.0	260.2	30.3	55,427.84

Related Shares
Persimmon (PSN), Taylor Wimpey (TW.), Trafalgar New (TRAF), John Lewis Of Hungerford (JLH)

Reckitt Benckiser (RB.) Latest News

Reckitt Benckiser News

Date	Time	Source	Headline
23/6/2017	11:00	UKREG	Reckitt Benckiser Group PLC Publication of a Prospectus - Replacement
22/6/2017	17:26	UKREG	Reckitt Benckiser Group PLC Publication of a Prospectus
22/6/2017	16:19	UKREG	Reckitt Benckiser Group PLC Director/PDMR Shareholding
22/6/2017	10:08	UKREG	Reckitt Benckiser Group PLC Director/PDMR Shareholding
22/6/2017	07:53	DJN	Reckitt Benckiser Prices $7.75 Billion Multi-tranche Senior Notes Offering
22/6/2017	07:00	UKREG	Reckitt Benckiser Group PLC Issue of Debt
21/6/2017	10:53	DJFR	L'eldorado américain des M&A devient plus exigeant pour les groupes..
19/6/2017	11:47	UKREG	Reckitt Benckiser Group PLC Director/PDMR Shareholding
15/6/2017	14:28	DJN	Reckitt Benckiser Group PLC Completion of MJN Acquisition
15/6/2017	13:58	UKREG	Reckitt Benckiser Group PLC Completion of MJN Acquisition

More Reckitt Benckiser News

Reckitt Benckiser Takeover Rumours

Reckitt Benckiser (RB.) Share Charts

1 Year Reckitt Benckiser Chart

1 Month Reckitt Benckiser Chart

Intraday Reckitt Benckiser Chart

Reckitt Benckiser (RB.) Discussions and Chat

Reckitt Benckiser Forums and Chat

Date	Time	Title	Posts
01/6/2017	13:35	RB.	623
12/4/2017	10:54	RECKITT BENCKISER _ ACTIVE INVESTORS CLUB (RB.)	6
16/8/2011	05:39	Cillit Bang	6
10/8/2011	10:22	RB Durex Viagra Condom	7
03/8/2011	14:46	Buy Reckitts for growth	23

Add a New Thread

Reckitt Benckiser (RB.) Most Recent Trades

Trade Time	Trade Price	Trade Size	Trade Value	Trade Type
16:14:58	7,928.00	2	158.56	NT
16:14:17	7,946.41	2	158.93	NT
16:13:28	7,944.00	24	1,906.56	NT
16:05:57	7,925.77	1,002	79,416.21	NT
16:05:57	7,925.77	3,167	251,009.09	NT

View all Reckitt Benckiser trades in real-time

Reckitt Benckiser (RB.) Top Chat Posts

Date	Subject
27/6/2017 09:20	Reckitt Benckiser Daily Update: Reckitt Benckiser is listed in the Household Goods & Home Construction sector of the London Stock Exchange with ticker RB.. The last closing price for Reckitt Benckiser was 7,960p. Reckitt Benckiser has a 4 week average price of 7,747p and a 12 week average price of 7,015p. The 1 year high share price is 8,108p while the 1 year low share price is currently 6,496p. There are currently 703,042,125 shares in issue and the average daily traded volume is 1,030,609 shares. The market capitalisation of Reckitt Benckiser is £55,427,841,135. Read Full Thread Reply
15/2/2016 12:18	spacecake: Some good news today as seen in the share price. Read Full Thread Follow Reply
15/2/2013 18:17	agai: Report about 5 months ago suggested overbought price position at £36! With consumer spending on the retreat, why any broker would and subsequent rampers would believe this price is sustainable, begs belief!! Retreat towards £30/£33 at the very least. ""Corporate results have been mixed, with those exposed to consumer spending suffering at large, as disposable income dries up. Reckitt Benckiser (LON:RB.), the household goods maker behind brands such as Dettol, Cillit Bang, Durex, and Nurofen, warned last week there was a tough outlook for consumer spending in mature markets as it posted only a slight rise in profit. Rival Unilever recently warned that consumer companies are operating in a deteriorating global economy as it reported a small drop in net profit, while US based market leader Procter & Gamble has issued two profit warnings this year, blaming waning demand in mature markets. Unilever, however, is further down the line in the battle to secure customers in new geographical markets and with further pain expected in Western markets, Reckitt's margins are likely to be squeezed further. The oscillators, however, are overbought, suggesting the recent momentum may be fading. At the time of writing the share price is 3599p and I believe a short trade with a stop-loss above the multi-year highs at 3707p offers an attractive risk / reward bias. Near term targets are seen at 3455p, 3329p and 3168p"" Read Full Thread Follow Reply
15/2/2013 14:25	stever4545: Show the main post> Stever4545 - 15 Feb 2013 - 09:43 - 119 of 128Sorry : it's on Schwab siteStever4545 - 15 Feb 2013 - 09:43 - 120 of 128Range ?31 to ?39Stever4545 - 15 Feb 2013 - 09:50 - 121 of 128Colgate and oral health seen as going ahead emphasis on emerging marketsAdditional manufacturing ability on SAFurther supply chain and cost base efficienciesCentralisation of Deo UK manufacturing in enhanced Port Sunlight facilityStever4545 - 15 Feb 2013 - 10:12 - 122 of 128Gone into auctionStever4545 - 15 Feb 2013 - 11:13 - 123 of 128Colgate and oral health seen as going ahead emphasis on emerging marketsAdditional manufacturing ability on SAFurther supply chain and cost base efficienciesCentralisation of Deo UK manufacturing in enhanced Port Sunlight facilityStever4545 - 15 Feb 2013 - 11:21 - 124 of 128Feb 13 Global USG 9.72%Stever4545 - 15 Feb 2013 - 12:14 - 125 of 128Stever4545 - 15 Feb 2013 - 12:13 - 60 of 60Predicted Q1 result seen as making trading range ?29 to ?31Stever4545 - 15 Feb 2013 - 12:37 - 126 of 128Colgate and oral health seen as going ahead emphasis on emerging marketsAdditional manufacturing ability on SAFurther supply chain and cost base efficienciesCentralisation of Deo UK manufacturing in enhanced Port Sunlight facilityStever4545 - 15 Feb 2013 - 12:40 - 127 of 128Everyone that works here shares Polmans vision to double the size of the CompanyTo half the ecological footprintAnd to double the share priceStever4545 - 15 Feb 2013 - 12:43 - 128 of 128168 000 people that all believe> Read Full Thread Follow Reply
14/2/2013 10:54	batman9: Canaccord Genuity has upgraded its recommendation on multinational household goods giant Reckitt Benckiser [LON:RB.] to 'add' from 'hold' after the company announced better-than-expected full-year results for 2012. The City broker has increased its price target significantly to 4,700 pence from 3,730 pence. Earnings per share estimates have been increased to 285.4 pence from 257.8 pence for 2013. Analyst Chris Wickham said: "2012 results comfortably beat both our own and market expectations. "Moreover, Reckitt raised its one-year forward sales growth guidance to +5% to +6% from +4% previously. "We adjust our 20013 EPS forecasts upwards by 11%, raise price target from 3,730p to 4,700p and upgrade from hold to add." At 8:58am: Reckitt Benckiser share price was up 75.5 pence at 4,494.5 pence. http://www.brokerforecasts.com/news/article/articleId/4538477 Read Full Thread Follow Reply
04/12/2012 22:45	apad: "Reckitt Benckiser's largest shareholder JAB Holdings to sell £1.3bn stake to fund Avon bid. The holding company, controlled by German billionaires the Reimanns, holds a 15.5pc stake in Reckitt. The sale was announced after the market closed, with 36m shares, about 4.9pc of the company, being offered at a price of £32.50 to £34." Lot of shares mopped up since then. From geswan:"Elephants don't gallop but if ever there was a galloping elephant its RB. Not just 2 or 3 years out but for ten years as well imho. Their brands are all household names, they have grown div, sales and EPS every year since 2000 (including 2008/9) and have a high margin. Share price since 2000 has over 400% growth (33% pa) with low volatility. Whats not to like with +3% yield?" apad Read Full Thread Follow Reply
08/11/2012 16:20	apad: Came across this on the Zulu thread: henryatkin 2 Nov'12 - 10:34 - 1322 of 1341 Simon42 ...Slater says elephants don't gallop but if ever there was a galloping elephant its RB. Not just 2 or 3 years out but for ten years as well imho. Their brands are all household names, they have grown div, sales and EPS every year since 2000 (including 2008/9) and have a high margin. Share price since 2000 has over 400% growth (33% pa) with low volatility. Whats not to like with +3% yield? Succinct comment. apad Read Full Thread Follow Reply
08/2/2012 19:21	apad: More from FT Revealing Reckitt Benckiser's strategy, Rakesh Kapoor promised to "leave no question answered." His slick presentation certainly impressed investors, and revealed a streak of derring-do few other companies would dare run their US division out of Amsterdam, for example. And it drove the share price up 3 per cent in the process. As a case for a re-rating of the stock, now trading close to decade-lows, Mr Kapoor's presentation was impeccable. But he failed to deliver on that initial promise. The 16 "power countries" the company is focusing on remain shrouded in mystery due to "commercial sensitivities". It also remains less than clear how straightforward it will be to run an American operation from across a rather large ocean. This is even more so at a time when peer companies, including Unilever and drinks maker Diageo, are splitting regions into smaller organisational units rather than enlarging them. None of this seemed overly to concern the investment community. "Reckitt has passed the baton to the new generation of managers after what has been a great historical performance and shown the market there is still huge potential," said Harold Thompson, analyst at Deutsche Bank, house broker. That potential comes as it does for virtually every consumer goods multinational from emerging markets. These account for some 38 per cent of revenues, and Reckitt is targeting 45 per cent by 2016. Technically, it is targeting 50 per cent, but Asia includes the developed markets of Japan, Australia and New Zealand. However, Reckitt was a late passenger on the bandwagon, resulting in weaknesses such as China which Mr Kapoor acknowledges. It is also ramping up in these markets at a time when growth is decelerating, albeit to levels still buoyant compared with developed markets. Mr Kapoor denies any suggestion of catch-up. "We have one of the best track records of growth in emerging markets," he said. While China is "not as good as we would like," he notes that the acquisition of SSL, maker of Scholl sandals and Durex condoms, doubled turnover in the country. The focus on emerging markets means more resource allocation. Now, half of the company's £200m annual capital expenditure goes into the region. That will rise to 80 per cent in 2016. Marketing spend will also increase, from 44 per cent of the total budget to 55 per cent, as will that for senior management. But what investors liked about the strategy is the underpinnings remain the same: top-line growth ahead of the market, steadily expanding operating margins (apart from this year when they will stay flat) and strong cash conversion. Nor is the company holding off spending during its "year of transition". Marketing spend will rise by £100m, which analysts estimate to be a rise of 10 per cent. This will be mostly self-financed by cost-cutting programmes elsewhere. "They've changed the packaging rather than the recipe," said Guillaume Delmas, analyst at Nomura. "Clearly nothing is broken. They are just going to continue the momentum." In the past, under Bart Becht, who handed over the reins to Mr Kapoor last year, that translated into hefty outperformance. Returns from Reckitt left rivals in the shade, not least because superior products won over consumers. The departure of Mr Becht, along with wobbles in performance, reversed that. Measured over the past two years, shareholder returns have lagged those of peers. So has Mr Kapoor done enough to win a re-rating? For some, Like Martin Deboo at Investec, there is a valuation conundrum "because growth has lost some of its lustre but cash generation remains strong". Another analyst cautions that Reckitt is still "a bit of a show-me story." Having unveiled big changes, they need to deliver on execution before meriting a higher multiple, he says. But others reckon its fortunes are already on the turn. "Overall group growth and earnings prospects are as good as ever, and given the valuation is close to 10-year lows, there is room for a re-rating," says Mr Thompson. Read Full Thread Follow Reply
27/10/2011 08:51	philanderer: Questor share tip: Quarterly outlook a headache for Nurofen maker Investors in Reckitt are likely to be reaching for the Nurofen after quarterly results from the consumer products giant prompted a significant fall in its share price. Questor says hold. http://www.telegraph.co.uk/finance/markets/questor/8851433/Questor-share-tip-Quarterly-outlook-a-headache-for-Nurofen-maker.html Read Full Thread Follow Reply
16/8/2011 05:39	deltar: A large number of stever46 posts have now been deleted from the product recall thread. I assume that this is because they were at best incorrect and in the worst case misinformation. Its good that they have been removed but the company have the original posts which were in the public domain on this website from the date they were posted up until last weekend. Anyone reading those posts would have been mislead into thinking that there is a problem with Cillit Bang and may have been influenced into selling shares, thus damaging the share price. Read Full Thread Follow Reply
14/4/2011 13:23	dawntrader: good op to get into a great co .. in my view ....... also Reckitt Benckiser's share price took a beating Thursday after the group announced the retirement of chief executive officer Bart Becht. Japanese broker Nomura says that while this isn't ideal, "we stay the course" and keeps its positive stance on the household products group. "We are not surprised by the share price reaction to the announcement...given [Becht's] personal association with the success of the company over the past 10 years," said the broker. Nomura suggests that the market was expecting him to stay in the role for some time yet, and will question the succession planning and timing following the departure of the long-term serving and well-regarded chief financial officer Colin Day announced in October. However, the broker says it is convinced that there is an underappreciated growth story in Developing Markets, potential to develop the Health & Personal Care franchise, and valuation upside to Suboxone. A 'buy' rating and 3,800p target price are maintained. --- Read Full Thread Follow Reply

Reckitt Benckiser share price data is direct from the London Stock Exchange

Your Recent History

LSE

GKP

Gulf Keyst..

LSE

QPP

Quindell

FTSE

UKX

FTSE 100

LSE

IOF

Iofina

GBPUSD

UK Sterlin..

Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US Finance Manila

P:32 V: D:20170627 21:00:22